← All trials
NCT07195149
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Oct 31, 2025
- Primary completion
- Apr 30, 2030
- Completion date
- Nov 30, 2030
- First posted
- Sep 26, 2025
- Last posted
- Sep 26, 2025
- Enrollment
- 1703
- Arms / groups
- 3 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Dolnośląskie Centrum Chorób Serca im.prof. Zbigniewa Religi MEDINET Sp. z o.o.Lead sponsor
- Government of PolandCollaborator
- Dolnośląskie Centrum Chorób Serca im.prof. Zbigniewa Religi MEDINET Sp. z o.o.Sponsor investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.